Clinical trial NCT06874270: Metabolic Phenotyping for Personalized Obesity Therapy
Official title: Establishment of a Specific Metabolic Phenotyping for the Personalization of Obesity Therapy in Morbidly Obese Individuals
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obesity and Overweight
Keywords: obesity
metabolic phenotype
thrifty
spendthrift
weight loss
indirect calorimetry
fasting
meal test
VLCD
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
First posted: 2025-03-13
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of adult men and women (ages 18 to 70) with a body mass index (BMI) above 40 kg/m² who are receiving care at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel. All participants are enrolled in a multimodal obesity therapy program that includes nutritional counseling, behavioral interventions, and exercise components. Eligible individuals must meet the specified inclusion criteria and have no conditions that could confound study results or compromise patient safety.

Brief summary: This study aims to develop a simple, clinically applicable method for metabolic phenotyping to personalize obesity therapy in morbidly obese individuals. The underlying concept is that the way a person's resting metabolic rate (RMR) responds to a 24-hour fast can help distinguish between two metabolic phenotypes. Individuals with a "thrifty" metabolism show a significant drop in RMR during fasting, which may make them less responsive to conventional weight loss interventions. In contrast, those with a "spendthrift" metabolism exhibit little to no drop-or even a slight increase-in RMR, suggesting they may lose weight more readily.

The trial is designed as a prospective, single-center, longitudinal cohort study involving 20 morbidly obese patients (BMI \>40 kg/m²) who are already participating in a multimodal obesity therapy program. The study is divided into three phases. In the baseline phase, participants undergo comprehensive screening, which includes physical examinations, blood tests, and body composition assessments. RMR is measured using indirect calorimetry both before and after a 24-hour fasting period, and a device (Lumen™) is used to assess whether the body is primarily burning carbohydrates or fats.

After the fasting measurements, participants perform a low-protein meal test by consuming a specially calibrated chocolate beverage. Their RMR is then monitored at several time points to determine the energy required for digestion. Following this, the study moves into the very-low-calorie diet (VLCD) phase, where participants consume approximately 800 kcal per day using formula meals tailored to meet their nutritional needs despite the calorie restriction. During this 12-week phase, changes in body weight, composition, and metabolic parameters are closely monitored.

The final phase of the study is a 12-week weight maintenance period, during which the focus is on sustaining the achieved weight loss. In addition to RMR and dietary assessments, advanced techniques such as metabolomics are employed. Blood, urine, and saliva samples are collected to analyze metabolic profiles and identify potential hormonal biomarkers-such as leptin, FGF21, and adrenaline-that could further differentiate the "thrifty" and "spendthrift" phenotypes. Body composition is also assessed using methods like bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod).

By correlating the changes in RMR with metabolic and hormonal markers, the study tests the hypothesis that individuals with a marked RMR decrease during fasting (the "thrifty" phenotype) may experience less weight loss during a hypocaloric diet compared to those with minimal RMR change (the "spendthrift" phenotype). If validated, this approach could allow clinicians to predict weight loss outcomes more accurately and tailor obesity treatments to the individual's unique metabolic profile.

Detailed description: This study is a prospective, single-center, longitudinal cohort trial designed to unravel the metabolic heterogeneity among morbidly obese individuals and to develop a clinically feasible method for metabolic phenotyping. The aim is to identify distinct metabolic responses to a controlled fasting period that may predict weight loss outcomes and guide personalized obesity therapy.

Potential participants are morbidly obese patients (BMI \>40 kg/m²) already enrolled in a multimodal obesity therapy program at the University Hospital Schleswig-Holstein, Campus Kiel. The screening process includes a thorough medical history, physical examination, and laboratory testing to exclude confounding conditions that might affect energy expenditure or the interpretation of metabolic measurements.

In the baseline phase, enrolled subjects undergo extensive assessments to characterize their metabolic status. Body composition is evaluated using several complementary techniques: bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod). These methods provide detailed insights into fat mass, lean mass, and overall body composition. Resting metabolic rate (RMR) is measured using indirect calorimetry, with subjects placed under a canopy (haubenkalorimeter) that records oxygen consumption and carbon dioxide production to yield precise energy expenditure data.

A critical component of the study is the evaluation of RMR before and after an extended fasting period. Initially, RMR is measured following a 12-hour overnight fast. Participants then complete a 24-hour fasting period, during which continuous monitoring-via devices such as a continuous glucose monitor-ensures compliance with the fasting protocol. A second RMR measurement is taken after the fasting period, and the percentage change in RMR is calculated. Based on previous research, a significant RMR reduction (≥5.7%) classifies a subject as having a "thrifty" metabolic phenotype, while a minimal reduction or slight increase (≥+3.8%) indicates a "spendthrift" phenotype. Subjects with intermediate changes are not categorized for the primary analysis.

Following the fasting assessments, participants undergo a low-protein meal test. They consume a standardized chocolate beverage calibrated to provide 50% of their baseline RMR in caloric content. Postprandial RMR is then measured at several intervals over a three-hour period to assess the thermic effect of food and the energy cost associated with digestion. This test helps to elucidate differences in nutrient oxidation and metabolic flexibility between the two phenotypes.

After completing the baseline phase, subjects enter a 12-week very-low-calorie diet (VLCD) phase. During this period, they consume approximately 800 kcal per day through nutritionally complete formula meals that are designed to maintain a balanced macronutrient profile despite severe caloric restriction. Weight, body composition, and metabolic parameters are monitored on a weekly basis to capture the effects of the dietary intervention. The hypothesis is that individuals with a "thrifty" metabolic response may lose less weight compared to those with a "spendthrift" response, owing to their reduced energy expenditure during fasting.

Following the VLCD phase, patients transition into a 12-week weight maintenance phase. In this period, the focus shifts to sustaining weight loss and monitoring long-term metabolic changes. RMR, body composition, and dietary intake continue to be assessed periodically. Participants also use an activity tracker to document daily physical activity, ensuring that variations in energy expenditure are accounted for in the analysis.

An innovative aspect of this study is the incorporation of metabolomic analysis to identify potential biomarkers linked to the metabolic phenotypes. Biological samples-including blood, urine, and saliva-are collected at various time points throughout the study. These samples undergo metabolomic profiling using advanced techniques such as liquid chromatography-mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) spectroscopy. The goal is to identify specific metabolites or patterns-such as variations in leptin, fibroblast growth factor 21 (FGF21), and catecholamines-that correlate with the magnitude of RMR change during fasting. This analysis may reveal novel biomarkers that predict weight loss responsiveness and metabolic health.

Data collection extends beyond metabolic measurements. Participants complete visual analog scales (VAS) to assess subjective feelings of hunger and satiety, providing insights into the behavioral dimensions of appetite regulation. In addition, continuous glucose monitoring and measurements of beta-hydroxybutyrate levels are used to verify fasting compliance and to ensure the accuracy of the metabolic assessments.

The study is managed by a multidisciplinary team led by Dr. Tim Hollstein, with contributions from specialists in endocrinology, diabetology, clinical nutrition, and metabolomics. Collaborations with experts from associated institutions enhance the methodological rigor and analytical capacity of the trial. Statistical power calculations, based on prior studies, indicate that approximately 20 subjects (10 per extreme phenotype group) are required to detect significant differences in weight loss outcomes. To accommodate variability and potential dropouts, an initial screening of around 80 individuals is planned.

Safety and compliance are paramount. The protocol includes rigorous monitoring for adverse events related to fasting, blood sampling, and the use of continuous monitoring devices. Subjects who do not meet fasting criteria-confirmed via continuous glucose readings or ketone measurements-are excluded from the primary analysis but continue to receive standard obesity therapy.

Ultimately, the study seeks to bridge the gap between complex laboratory-based measurements and practical clinical applications. By establishing a reliable and straightforward method for metabolic phenotyping, it aims to enable personalized obesity treatments that are tailored to an individual's unique metabolic profile. This approach could revolutionize obesity management by providing clinicians with predictive tools to optimize weight loss interventions and improve long-term metabolic outcomes.

Eligibility criteria: Inclusion Criteria:

* Morbid obesity (BMI \> 40 kg/m²)
* Currently undergoing a multimodal obesity therapy program at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel

Exclusion Criteria:

* Type 1 or Type 2 diabetes mellitus, or fasting blood glucose \>125 mg/dL, or HbA1c \>6.5%
* Conditions affecting appetite or energy expenditure (e.g., Cushing's syndrome, uncontrolled hyper-/hypothyroidism, diabetes mellitus)
* Gastrointestinal diseases that may impair nutrient absorption (e.g., inflammatory bowel disease, malabsorption syndromes, peptic ulcers)
* Psychiatric disorders that influence eating behavior (e.g., active depression, anorexia nervosa, bulimia nervosa, borderline personality disorder)
* Acute, unstable cardiovascular disease requiring hospitalization within the last 6 months (e.g., stent implantation)
* Cancer requiring treatment within the past 5 years
* Chronic kidney disease at Stage IV or worse according to NKF criteria
* Active infectious disease (e.g., HIV, hepatitis)
* Active nicotine use
* Drug use (e.g., amphetamines, cocaine, heroin, marijuana)
* Regular intense physical activity (≥1 hour of sport per day)
* Non-MRI-compatible metallic implants (e.g., joint replacements, metal plates)
* Pregnancy or breastfeeding
* Use of weight-loss medications
* Clinically relevant claustrophobia
* Any other condition not specified above that, in the judgment of the investigator, could interfere with study participation or compromise patient safety

Primary outcomes:
measure: Change in Resting Metabolic Rate (RMR) From Baseline to 24 Hours After Fasting
timeFrame: Baseline to Week 12
Secondary outcomes:
measure: Change in Plasma FGF21 From Baseline to 24 Hours After Fasting
timeFrame: Baseline, after 24-hour fast, and throughout the 6-month study period (up to Week 26)
measure: Meal-Induced Thermogenesis as a Predictor of Weight and Fat Mass Loss
timeFrame: Day 1 (immediately following 24-hour fast) for the low-protein meal test, with follow-up assessments at Week 12 (end of VLCD) and Week 26 (end of weight maintenance).
measure: Metabolic Flexibility (Respiratory Quotient Changes)
timeFrame: Baseline (Day 0), after 24-hour fast (Day 1), and during the low-protein meal test (Day 1)
measure: Subjective Hunger After 24-Hour Fast
timeFrame: Baseline (Day 0) and after 24-hour fast (Day 1)
measure: Changes in Fat Mass During and After a Hypocaloric Diet
timeFrame: Baseline, Week 12 (end of VLCD), and Week 26 (end of maintenance phase)
measure: Gut Microbiome Differences
timeFrame: Baseline, Week 12, and Week 26
measure: Thermogenic and Appetite-Regulating Hormone Composite Index
timeFrame: Baseline, after 24-hour fast (Day 1), Week 12, and Week 26
measure: Long-Term Change in Metabolic Phenotype
timeFrame: Baseline, Week 12, and Week 26
measure: Association of RMR Changes With Meal-Induced Thermogenesis
timeFrame: Baseline (Day 0) and during low-protein meal test (Day 1)
measure: Association Between CO₂ Production and Energy Expenditure
timeFrame: Baseline (Day 0), after 24-hour fast (Day 1), and throughout the 6-month study period
measure: Correlation Between Resting Metabolic Rate and Respiratory Quotient
timeFrame: Baseline (Day 0), after 24-hour fast (Day 1), and during subsequent diet phases (up to Week 26)
measure: Correlation Between Diet-Induced Thermogenesis (DIT) and Postprandial FGF21 Levels
timeFrame: During the low-protein meal test (Day 1) and optionally at subsequent time points (Week 12, Week 26)
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: University Hospital Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
References: